Business Description

First Wave BioPharma Inc
NAICS : 325412
SIC : 2834
ISIN : US05502L1052
Description
First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 14.25 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 74.7 | |||||
3-Year EPS without NRI Growth Rate | 76.5 | |||||
3-Year FCF Growth Rate | 71 | |||||
3-Year Book Growth Rate | -80.3 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 74.6 | |||||
9-Day RSI | 68.94 | |||||
14-Day RSI | 61.92 | |||||
6-1 Month Momentum % | -79.36 | |||||
12-1 Month Momentum % | -94.49 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.6 | |||||
Cash Ratio | 1.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -327.2 | |||||
Shareholder Yield % | -185.5 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -1068.7 | |||||
ROA % | -303.01 | |||||
ROIC % | -602.06 | |||||
ROC (Joel Greenblatt) % | -5070.92 | |||||
ROCE % | -940.03 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.3 | |||||
Price-to-Tangible-Book | 2.59 | |||||
EV-to-EBIT | -0.08 | |||||
EV-to-EBITDA | -0.08 | |||||
EV-to-Forward-Revenue | -64.47 | |||||
EV-to-FCF | -0.09 | |||||
Price-to-Net-Current-Asset-Value | 3.11 | |||||
Price-to-Net-Cash | 6.22 | |||||
Earnings Yield (Greenblatt) % | -1250 | |||||
FCF Yield % | -345.89 |
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FWBI
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
First Wave BioPharma Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -19.094 | ||
Beta | 0.96 | ||
Volatility % | 77.38 | ||
14-Day RSI | 61.92 | ||
14-Day ATR ($) | 0.026712 | ||
20-Day SMA ($) | 0.278245 | ||
12-1 Month Momentum % | -94.49 | ||
52-Week Range ($) | 0.222 - 8.959999 | ||
Shares Outstanding (Mil) | 13.5 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
First Wave BioPharma Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
First Wave BioPharma Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
First Wave BioPharma Inc Frequently Asked Questions
What is First Wave BioPharma Inc(FWBI)'s stock price today?
The current price of FWBI is $0.31. The 52 week high of FWBI is $8.96 and 52 week low is $0.22.
When is next earnings date of First Wave BioPharma Inc(FWBI)?
The next earnings date of First Wave BioPharma Inc(FWBI) is .
Does First Wave BioPharma Inc(FWBI) pay dividends? If so, how much?
First Wave BioPharma Inc(FWBI) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |